Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Reducing Harms in Lung Cancer Screening—Bach to the Future

Reducing Harms in Lung Cancer Screening—Bach to the Future Opinion EDITORIAL Reducing Harms in Lung Cancer Screening— Bach to the Future Michael Incze, MD, MSEd; Rita F. Redberg, MD, MSc The US Preventive Services Task Force currently recom- gible for LCS using the Bach risk tool, a validated risk model mends screening (grade B recommendation) for lung cancer using sex, age, smoking duration, duration of abstinence from with annual low-dose computed tomography for high-risk in- smoking and number of cigarettes smoked per day as inputs. dividuals ages 55 to 80 years, defined as those having greater The astoundingly high rates of false-positive results in the low- than a 30 pack-year cumula- est risk quintiles (eg, 2221 false-positive results per lung can- tive smoking history and hav- cer death averted and a NNS of nearly 5600 in quintile 1), as Related article page 426 ing quit within the past 15 well as extremely low rates of lung cancer incidence in the low- years. The evidence to sup- est-risk groups, confirm trends illustrated in previous stud- 12,13 port this recommendation overwhelmingly comes from the Na- ies and make the case for refined guidelines for LCS. This tional Lung Cancer Screening Trial (NLST). While 3 other large is especially salient in http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Internal Medicine American Medical Association

Reducing Harms in Lung Cancer Screening—Bach to the Future

JAMA Internal Medicine , Volume 178 (3) – Mar 22, 2018

Loading next page...
 
/lp/american-medical-association/reducing-harms-in-lung-cancer-screening-bach-to-the-future-kcEgrz4mZd
Publisher
American Medical Association
Copyright
Copyright 2018 American Medical Association. All Rights Reserved.
ISSN
2168-6106
eISSN
2168-6114
DOI
10.1001/jamainternmed.2017.8217
Publisher site
See Article on Publisher Site

Abstract

Opinion EDITORIAL Reducing Harms in Lung Cancer Screening— Bach to the Future Michael Incze, MD, MSEd; Rita F. Redberg, MD, MSc The US Preventive Services Task Force currently recom- gible for LCS using the Bach risk tool, a validated risk model mends screening (grade B recommendation) for lung cancer using sex, age, smoking duration, duration of abstinence from with annual low-dose computed tomography for high-risk in- smoking and number of cigarettes smoked per day as inputs. dividuals ages 55 to 80 years, defined as those having greater The astoundingly high rates of false-positive results in the low- than a 30 pack-year cumula- est risk quintiles (eg, 2221 false-positive results per lung can- tive smoking history and hav- cer death averted and a NNS of nearly 5600 in quintile 1), as Related article page 426 ing quit within the past 15 well as extremely low rates of lung cancer incidence in the low- years. The evidence to sup- est-risk groups, confirm trends illustrated in previous stud- 12,13 port this recommendation overwhelmingly comes from the Na- ies and make the case for refined guidelines for LCS. This tional Lung Cancer Screening Trial (NLST). While 3 other large is especially salient in

Journal

JAMA Internal MedicineAmerican Medical Association

Published: Mar 22, 2018

References